HIV and Challenges of Vaccine Development
|
|
- Alvin Walton
- 6 years ago
- Views:
Transcription
1 Dale and Betty Bumpers accine Research Center ational nstitute of Allergy and nfectious Diseases ational nstitutes of Health H and Challenges of accine Development Richard A. Koup, MD
2 What Mediates accine-induced Protection? RUS YPE OF ACCE ACCE-DUCED PROECO MMUE COROL Smallpox Live Antibodies, CL CL Rabies Killed virus Antibodies Antibodies, CD4, CL Polio Live or killed virus Antibodies Antibodies accine-induced antibodies (neutralizing) most commonly protect against viral infections. Measles Live Antibodies; CL Antibodies, CD4, CL Mumps Live Antibodies Antibodies Rubella Live Antibodies Antibodies aricella zoster Live Antibodies; CL Antibodies, CL Little evidence that cells actually mediate protection against viral challenge. nfluenza Protein Antibodies Antibodies, CD4, CL Hepatitis A Killed virus Antibodies Antibodies, CD4, CL Hepatitis B Protein Antibodies Antibodies, CD4, CL HP LP Antibodies CD4, CL However, once infected, cells are clearly involved in mediating viral control. Hepatitis C CD4, CL Cytomegalovirus CD4, CL Epstein-Barr virus CD4, CL HS types 1 and 2 CL H-1 and H-2 CD4, CL HH 6 Antibodies, cells
3 herefore Efforts should be directed towards developing immunogens that stimulate neutralizing antibodies t has been difficult to induce neutralizing antibodies to H ariable loops Envelope is heavily glycosylated Shielding of neutralization domains Multiple clades of H with only limited crossneutralization Early vaccines generated binding, but not neutralizing, antibodies
4 History of Efficacy rials axgen gp120 Canarypox/gp120 R 144 Merck 023/H 502 (SEP) rad5 gag/pol/nef H 503 (Phambili) DA/rAd5 env/gag/pol/nef H 505 Enrollment Follow-up Final analysis nterim analysis
5 History of Efficacy rials axgen gp120 Canarypox/gp120 R 144 Merck 023/H 502 (SEP) rad5 gag/pol/nef H 503 (Phambili) DA/rAd5 env/gag/pol/nef H 505 Enrollment Follow-up Final analysis nterim analysis
6 SEP/Phambili mmunogenicity Merck rad5 expressing H clade B Gag, Pol, and ef Strong ELSpot and CD8 responses to H Gag, Pol, and ef o Env, so no binding or neutralizing antibodies Expected result: o effect on acquisition Positive effect on lowering virus load
7 Lack of Efficacy in the SEP rial: Merck rad H accine rad5 vaccine expressing Clade B Gag, Pol, ef Cumulative umber of H nfections: M population (males) Cumulative number of H infections (events) o 20 Effect on iral 20 Load Ad accine 24 Placebo Cumulative number of H infections (events) Ad5 > accine 9 Placebo ime to event (weeks) ime to event (weeks) ncreased acquisition among Ad5 seropositive volunteers: 1) Unrelated to Ad-specific CD4 cells as targets for infection 2) Associated with lack of circumcision 3) Associated with HS-2 serostatus (but unrelated to vaccine)
8 History of Efficacy rials axgen gp120 Canarypox/gp120 R 144 Merck 023/H 502 (SEP) rad5 gag/pol/nef H 503 (Phambili) DA/rAd5 env/gag/pol/nef H 505 Enrollment Follow-up Final analysis nterim analysis
9 Modest Efficacy in R144: An Effect on Acquisition ALAC -H (vcp1521) Canarypox expressing H-1 subtype E gp120 and H-1 subtype B gag and protease ADSAX B/E H gp120 from subtype E and subtype B
10 accination and Follow-up Schedule H test, risk assessment and counseling (time in years) 6 month vaccination schedule 3 years of follow up (every 6 mo.) ALAC H (vcp1521) priming at week 0, 4, 12, 24 ADSAX B/E gp120 boosting at week 12, 24 accine:placebo = 1:1
11 Efficacy (m) 52,985 person-years 125 infections accine infections: 51 Placebo infections: 74 E: 31.2% p= % C: 1.1, 52.1 (O Brien-Flemingadjusted)
12 Summary of Analyses m PP (# subjects) 16,402 16,395 12,542 Person years 52,985 52,985 36,720 accine/placebo (event #) 56 / / / 50 accine efficacy 26.4% 31.2% 26.2% 2-sided p value % confidence interval -4.0, , , 51.9 ncludes 5 vaccine and 2 placebo recipients who were H positive at baseline Decreased event numbers, lower precision
13 F- /L-2 CS 6 months post-final vaccination Frequency (%) CD4 CD8 Antigen P P Env Only 45/142 (32) * 1/54 (2) 5/133 (4) 4/52 (8) Gag Only 0/144 0/56 3/136 (2) 1/53 (2) Env + Gag 2/142 (1) 0/54 0/131 0/51 Any H 47/142 (33)* 1/54 (2) 8/131 (6) 5/51 (10) *P < compared to placebo
14 Binding Antibody 2 weeks post-final vaccination Antigen Frequency (%) Reciprocal GM B gp /142 (99) ( ) E gp ( ) B p24 74/142 (52) 138 ( ) P< compared to placebo group all Antigens Only eutralize ier 1 iruses
15 Efficacy at 1 year appeared higher (Kaplan-Meier-based estimates) m PP month Events Efficacy Events Efficacy % n/a n/a % 21 68% % 41 41% % 53 27% % 62 31% Can we build on this early efficacy?
16 Pox Protein Development Plan (Draft) Ongoing R144 Follow up in hailand Studies: R144i immune correlates studies R305 protein boosting study R306 expanded immunogenicity study Objective: Determine correlate of protection for use in future trials; optimize the regimen Partners/Funders: US Army, hai Gov t, H, sanofi pasteur, BMGF Candidate selection Research ALAC is default vector prime Proteins boosts BD R144 immune correlates mmune grid Cost, product availability Population: Heterosexual, high risk Products: DA + YAC (sanofi) + gp140 (Polymun)/MF59 (D) vs. YAC (sanofi) + gp140 (Polymun)/MF59 (D) Objective: Extend results & accelerate evaluation of other products using adaptive trial design and first available protein Partners/Funders: H, H, sanofi pasteur, ovartis, BMGF Licensure S. Africa ph2b hailand ph2b Population: MSM, high risk Products: ALAC (sanofi) + gp120/mf59 (D) Objective: Confirm result & demonstrate efficacy in target population with potential for licensure Partners/Funders: US Army, hai Gov t, H, sanofi, BMGF? Africa ph2b Population: Heterosexual, high risk Products: ALAC (sanofi) + gp120/mf59 (D) Objective: Extend result & translate vaccine to Africa, other highrisk groups Partners/Funders: H, H, sanofi, ovartis, BMGF, RSA?
17 R 144 Correlates Discovery Effort mplications for future clinical development of this product Humoral & nnate mmunity Cellular mmunity Host Genetics Animal Models Scientific Advisory Groups ADSORY GROUPS Product Development Advisory Group Scientific Steering Committee mplications for future scientific inquiry into the result and evaluation/design of other candidates and studies PA H Steering Committee R144 Steering Committee MHRP - DADS Steering Committee
18 R144 Correlates Research: Collaborating nstitutions 35 investigators from 20 institutions working on 32 different assays (~150 total staff) Cornell, Duke, Harvard, UCSC, UC, Rush, U Mass, orthwestern, YU, U Wash, Oxford, Kings College, Mahidol, St. George s, U Melbourne, Scripps, H/UMD, G/OSHU, MHRP, Monogram Bio, H (AD, C)
19 wo Phases of Correlates Discovery Phase ( March 2011) Broad survey of innate, humoral, systems biology, genetic, and cellular assay evaluation/comparison. Multiple Bab, ab, ADCC, ADC approaches Statistical plan Phase (March July 2011) Case-control Evaluation of a broad range of assays but with downselection to optimize the statistical design specimens have been shipped to collaborating labs in the past few weeks.
20 R144 rial: Cellular mmune Analyses Cellular mmunity WG (McElrath) cells: Antigen-specific CD4+ & CD8+ cells Composite assay ntracellular cytokine staining Soluble mediators (Luminex) ranscriptional arrays (PBMC) Proliferation (CFSE) Epitope mapping Functional phenotypes B cells: gp140-binding ELSpot functional phenotypes K cells: polyfunctionality receptor expression Monocytes, mdcs: phagocytosis
21 he Antigen: A244 gd+ gp120 (component of ADSAX) A K L H L S R S 310 G P G E Q S 320 P K 3 S R R C F Y E C Y A K R E D G G R 4β7 bs D 340 E G 350 E A L S G L L L 200 F G 290 Q E K L D 280 P W 360 F Y A L K G 260 S 420 E D P S S 270 K A G Q C C A L H D K Q C H P C 2 4 K G K E K 250 C K P Y L H G 240 E A 210 A Y G K C Q D K 190 P L 370 H E K F S F L K G K P 410 R D R Y E S Q D 230 L R S P L K C L M C P P K S F 380 E 220 K P 430 L C F P P C C P K F L 130 S L G G S P P Q C 180 Y K 140 S F 170 D K Q C H Q 390 D C E R L D E 120 W H F C R G E F 400 G 440 M Q E Q D A E S L M H M S C W S 460 Q 1 G G 150 L M 110 G F E A K W M L S 450 G K L A Q A E A H W P L 100 L P A Y M R R 470 H A C P D G P D C1 G D Q E A 80 S C E D A P K Y A L A D F L 490 A E A K A 70 D K G S L D K G H A W R M A D R G E G 5 P G H L P G R F E R K 60 F E W A P 50 D L G R E K R COOH R F 510 L G E K P L L D Q L L E P Y L K Y K Q E P R A R R 500 HS gd A K 520 G L R A A A G G M H 2 Amino acid sequence inside circles represents A244 gp120 gd(+). (adapted from Leonard, et al.,j.biol. Chem. 265, 10373, 1990).
22 Linear 2 Peptide Binding 4 7 binding epitope Peptide umber H-infected R144 RC vaccine (DA/Ad5)
23 History of Efficacy rials axgen gp120 Canarypox/gp120 R 144 Merck 023/H 502 (SEP) rad5 gag/pol/nef H 503 (Phambili) DA/rAd5 env/gag/pol/nef H 505 Enrollment Follow-up Final analysis nterim analysis
24 H 505 Phase 2b, randomized, placebo-controlled trial to evaluate the safety and effect on post-h acquisition viremia of a multiclade H-1 DA plasmid vaccine followed by a multiclade H-1 recombinant adenoviral vector vaccine in H-uninfected, adenovirus type 5 neutralizing antibody negative, circumcised men who have sex with men
25 H 505: Schedule and Endpoints Prime Boost Study Groups Day 0 Wk 4 Wk 8 Wk 24 accine 675 DA DA DA rad5 Placebo 675 PBS PBS PBS FFB rial was powered for a viral load effect (SEP trial era) 45 H infection endpoints 90% power to detect 1.0 log 10 reduction in plasma L 80% power to detect 57% reduction in acquisition How do the antibody responses compare to R144? Should the trial size be increased to provide better power to detect an acquisition effect?
26 Study Design est sera from R144 and H204 by ELSA against five envelope proteins Sera: 50 vaccinees and 25 placebo recipients from R vaccinees from H204 (precursor to H 505) 5 clade B H infected donors ime points: 2-4 weeks post final vaccination and 6 months later Proteins: Env B-M Env E-A244 RC EnvA RC EnvB RC EnvC 25 placebo recipients were negative against all proteins. hose data are not included in the subsequent graphs.
27 Env Antibody iters: R144 and H204 R144 peak R144 6 months H204 peak H204 6 months H+ sera Conclusions: Both products induced predominantly type specific antibodies Similar peak titers Similar loss of titer over six months
28 eutralizing Antibodies: H204 Most vaccinees had no neutralizing antibodies A few had good neutralization against ier 1 viruses M and SF162 hese were tested at 1:10 dilution against ier 2 viruses D50 eutralization iter10000 M ier 1 SF162.LS % eutralization (1:10 serum dilution) ier 2 Clade A Clade B Clade C ML n= 2 n= 4 n= 4
29 Rationale for adding acquisition as a primary endpoint in H 505 R144 showed that a reduction in acquisition is possible with a vaccine regimen that does not induce broadly neutralizing antibodies. he H 505 vaccine regimen induces antibody responses of similar magnitude and function as those induced by the R144 regimen. he H 505 vaccine regimen induces equivalent CD4 cell responses and CD8 cell responses that are superior to those in R144. he Smac239 homologue of the H 505 vaccine regimen has been shown to reduce acquisition by ~50% in an S challenge model.
30 H 505: Schedule and Endpoints Prime Boost Study Groups Day 0 Wk 4 Wk 8 Wk 24 accine 1100 DA DA DA rad5 Placebo 1100 PBS PBS PBS FFB What will we learn at primary analysis? 66 total and 52 evaluable H infection endpoints 90% power to detect 1.0 log 10 reduction in plasma L 80% power to detect 50% reduction in acquisition
31 H 505 Accrual Opened - May 29, 2009 First enrollment - June 11, 2009 Original sites activated - September 2, 2009 Atlanta Bethesda Birmingham Boston Fenway Brigham Chicago Los Angeles ashville ew York Columbia Union Square Philadelphia San Francisco Rochester Seattle ew sites activated August 2010 Annandale Baylor Cleveland Dallas Denver East Midtown Orlando
32 ADS accine Clinical rials-works in Progress Michelangelo s Unfinished Atlas 2003: axgen - lack of protection by gp120 antibodies 2007: SEP - no viral load protection by rad5 Gag, Pol, ef (pure CD8 vaccine) 2009: R144-31% fewer infections from canarypox Gag, Pol, Env/gp120 boost 2011: H 505 DA/rAd5 expressing Gag, Pol, ef, and 3 Envs: powered for an acquisition effect n the battle between antibody and cell vaccines, antibodies appear to have won Questions: 1. Future of pure cell vaccines? 2. Response to Env important but 3. eutralizing vs non-neutralizing antibodies? 4. Can other platforms that include Env provide better protection, and if so, by what mechanism?
33 Results from H prevention trials Study Length Effect size of Study (C) H accine (hai R144) 3.5 y 31% (1, 51) 1% DF gel (Caprisa, Karim et al.) 2.5 y 39% (6, 60) DF/FC PrEP (iprex, Grant et al 2010) 1.2 y 44% (15, 63) 12 mo effect Circumcision (Orange Farm, Rakai, Kisumu) 0% % 57% (42, 68) Efficacy An H vaccine should be considered a component of a comprehensive approach to H prevention Prof. Glenda Gray, H Conference, ov 2010 Padian S, et al. Weighing the gold in the gold standard: challenges in H prevention research. ADS 2010, 24:
34 Dale and Betty Bumpers accine Research Center ational nstitute of Allergy and nfectious Diseases ational nstitutes of Health accine Research Center Gary abel Peter Kwong John Mascola Daniel Douek Robert Seder mmunology Core Bob Bailer & staff Laurie Lamoreaux Collaborators elson Michael Jerome Kim Larry Corey Julie McElrath Flow Cytometry Core Mario Roederer & staff Clinical rials Core Barney Graham Mary Enama & staff Brenda Larkin & staff Contractors ical Genec Community Advisory Board accine trial volunteers!
35 ACKOWLEDGEMES University of Washington And 16,402 hai men and women who participated in the trial
HIV and Challenges of Vaccine Development
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health HIV and Challenges of Vaccine Development Richard A. Koup, MD INTEREST
More informationHIV Vaccines: Basic Science
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health HIV Vaccines: Basic Science Richard A. Koup, MD 6 th INTEREST Workshop
More informationOngoing HVTN Trials. Protocol N Trial Collaborators HVTN HVTN VRC DAIDS. Study Product(s)
HVTN 076 17 HVTN DNA multiclade rad5 multiclade 09/2011 The study looks at the immune response of genital and rectal tissues to injections of a DNA vaccine followed by a recombinant adenovirus serotype
More informationPlanned Vaccine Trials to Follow-up on RV 144. Merlin Robb, MD Deputy Director for Clinical Research MHRP
Planned Vaccine Trials to Follow-up on RV 144 Merlin Robb, MD Deputy Director for Clinical Research MHRP Planned studies are mutually reinforcing and will amplify public health impact and regional relevance
More informationCombinatorial Vaccines for AIDS and other Infectious Diseases
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services Combinatorial Vaccines for AIDS
More informationStart Date* Sites Description
076 17 083 180 084 100 085 90 098 94 Inovio rad35 clade A clade A rad clade B clade B PENNVAX-GP IL-12 adjuvant September-11 Seattle The study looks at the immune response of genital and rectal tissues
More informationCorrelates of Immunity: RV144 - Lessons Learned
Correlates of Immunity: RV144 - Lessons Learned US Military HIV Research Program (MHRP) Nelson L. Michael, MD, PhD AIDS Vaccine 2010, Atlanta GA 01 October 2010 Outline RV 144 Correlates Discovery Towards
More information4/14/2016. HIV Vaccines and Immunoprotection: Where Are We? Learning Objectives. After attending this presentation, participants will be able to:
HIV Vaccines and Immunoprotection: Where Are We? Mark J. Mulligan, MD, FIDSA Distinguished Professor of Medicine Emory University School of Medicine Atlanta, Georgia FINAL: 04/01/16 Atlanta, Georgia: Friday,
More informationALVAC -HIV and AIDSVAX B/E Prime-Boost HIV-1 Preventive Vaccine Regimen. Results of the Thai HIV Vaccine Trial, RV144
ALVAC -HIV and AIDSVAX B/E Prime-Boost HIV-1 Preventive Vaccine Regimen Results of the Thai HIV Vaccine Trial, RV144 SupachaiRerks-Ngarm, PunneePittisutthithum, SorachaiNitayaphan, JaranitKaewkungwal,
More informationOngoing HVTN Trials (Enrolling, In Follow-up, and in Long Term Follow-up)
Ongoing HVTN Trials (, In, and in ) HVTN 085 90 HVTN VRC rad5 multiclade 02/2012 Boston - Brigham; Chicago; Nashville; New York - NYBC; New York - NYBC - Bronx; Philadelphia; Rochester; San Francisco;
More informationProgress in HIV Vaccine Development Magdalena Sobieszczyk, MD, MPH. Division of Infectious Diseases Columbia University Medical Center
Progress in HIV Vaccine Development Magdalena Sobieszczyk, MD, MPH Division of Infectious Diseases Columbia University Medical Center 1 Outline A short history of HIV vaccine design and development Describe
More informationStart Date* Sites Description
HVTN 076 17 HVTN HVTN 084 100 HVTN HVTN 085 90 HVTN HVTN 096 96 HVTN IPPOX EuroVacc GSID USMHRP HVTN 098 94 HVTN Inovio clade B AIDSVAX B/E clade C NYVAC clade C PENNVAX-GP IL-12 adjuvant September-11
More informationThe Kitchen Sink. Glenda Gray AIDS vaccine at the cross roads: how to adapt to a new preven9on age? Monday 7 th October, 2013, Barcelona
The Kitchen Sink Glenda Gray AIDS vaccine at the cross roads: how to adapt to a new preven9on age? Monday 7 th October, 2013, Barcelona The only important slide of my presentation. All efficacy trial in
More informationHIV 1 Preventive Vaccine Regimen. Community based Trial in Thailand V 144. for the MOPH TAVEG Collaboration
V ALVAC HIV and AIDSVAX B/E Prime Boost HIV 1 Preventive Vaccine Regimen Final Results of the Phase III Community based Trial in Thailand Supachai Rerks Ngarm, Punnee Pittisutthithum, Sorachai Nitayaphan,
More informationTrial Collaborators Start Date* Sites Stage HVTN BMGF IPPOX EuroVacc GSID. HVTN DAIDS GSK Sanofi Jun 2017
Ongoing s:, In, Health/AESI Contact(s) 096/EV04 106 107 108 110 A phase 1 double blind placebo-controlled clinical trial to evaluate the safety and to compare the priming ability of NYVAC alone versus
More informationHVTN P5 Vaccine Trials
HVTN P5 Vaccine Trials Erica Andersen-Nissen, PhD Director, Cape Town HVTN Immunology Laboratory Considerations for a Pan-African HIV Vaccine Development Agenda Kigali, Rwanda 16-17 March 2015 HVTN Mission
More informationAdvancing HIV Vaccines into Efficacy studies. Glenda Gray WHO PD VAC 7-9 September 2015 Geneva, Switzerland
Advancing HIV Vaccines into Efficacy studies Glenda Gray WHO PD VAC 7-9 September 2015 Geneva, Switzerland What we need to end AIDS: controlling viremia New classes of Drugs Point of care viral load &
More informationWhy are validated immunogenicity assays important for HIV vaccine development?
Why are validated immunogenicity assays important for HIV vaccine development? There is a need to compare immunogenicity of products in the pipeline, when similar or different in class when developed by
More informationMay HIV Vaccines: The Basics
May 2018 HIV Vaccines: The Basics Presentation Overview What is a vaccine? How would an HIV vaccine work? Where are we in the search? What is needed now? What is a Vaccine? A substance that teaches the
More informationHIV: RV 144 prime boost HIV vaccine efficacy study
HIV: RV 144 prime boost HIV vaccine efficacy study Nelson L. Michael, M.D., Ph.D Colonel, Medical Corps, U.S. Army Director US Military HIV Research Program (MHRP) Walter Reed Army Institute of Research
More informationHVTN Laboratory Program: Immunogenicity and Research Assays
HVTN Laboratory Program: Immunogenicity and Research Assays Erica Andersen-Nissen, PhD Director, Cape Town HVTN Immunology Laboratory Considerations for a Pan-African HIV Vaccine Development Agenda Kigali,
More informationThe History of HIV Vaccine Development
The History of HIV Vaccine Development a short story on 30 years of research å Dr. Jill Gilmour International AIDS Vaccine Initiative Barcelona, 6 October 2013 IAVI is a product-development partnership
More informationRecombinant Baculovirus Derived HIV-1 Virus-Like Particles Elicit Potent Neutralizing Antibody Responses
Recombinant Baculovirus Derived HIV-1 Virus-Like Particles Elicit Potent Neutralizing Antibody Responses Weimin Liu University of Alabama at Birmingham Introduction and Rationale Virus-like particles (VLPs)
More informationShould There be Further Efficacy Testing of T-T cell Based Vaccines that do not Induce Broadly Neutralizing Antibodies?
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services Should There be Further Efficacy
More informationInduction of Innate Immune Responses in HVTN 071: a Trial using the MRKAd5 gag/pol/nef Vaccine from the Step Study
Induction of Innate Immune Responses in HVTN 71: a Trial using the MRKAd5 gag/pol/nef Vaccine from the Step Study Erica Andersen-Nissen Vaccine and Infectious Disease Institute Fred Hutchinson Cancer Research
More informationNIAID Vaccine Research Center: A Mission to Prevent HIV Infection
NIAID Vaccine Research Center: A Mission to Prevent HIV Infection AIDS Vaccine Awareness Day 20 year anniversary May 18, 2017 Barney S. Graham, MD, PhD Deputy Director Origins of the VRC 1997 1998
More informationHigher priming doses enhance HIV-specific humoral but not cellular. responses in a randomized, double-blind phase Ib clinical trial of
Higher priming doses enhance HIV-specific humoral but not cellular responses in a randomized, double-blind phase Ib clinical trial of preventive HIV-1 vaccines Pierre-Alexandre Bart a,b, Yunda Huang c,
More informationHIV Vaccine. Sunee Sirivichayakul, Ph.D. Faculty of Medicine Chulalongkorn University. August 22, 2014
HIV Vaccine Sunee Sirivichayakul, Ph.D. Faculty of Medicine Chulalongkorn University August 22, 2014 Immunity Natural immunity Active natural immunity e.g., infection Passive natural immunity e.g., trans-placental
More informationEfficacy Results from the Step Study
Efficacy Results from the Step Study (Merck V520 Protocol 023/HVTN 502) A Phase II Test-of-Concept Trial of the MRKAd5 HIV-1 Gag/Pol/Nef Trivalent Vaccine CROI February 5, 2008 Boston, MA Rationale for
More informationHIV Vaccine. 15 September 2016 นพ.นคร เปรมศร ผ อ านวยการส าน กงาน โครงการศ กษาว คซ นเอดส ทดลอง
HIV Vaccine 15 September 2016 นพ.นคร เปรมศร ผ อ านวยการส าน กงาน โครงการศ กษาว คซ นเอดส ทดลอง GLOBAL STATISTICS 2015 17 million people were accessing antiretroviral therapy 36.7 million people globally
More informationTrials & Tribulations: on the way to cure: where do HIV Vaccines fit in? Glenda Gray SA HIV Clinicians Society Conference April, 2016
Trials & Tribulations: on the way to cure: where do HIV Vaccines fit in? Glenda Gray SA HIV Clinicians Society Conference 2016 13-16 April, 2016 Scope Rationale for an HIV vaccine RV144 study in Thailand
More informationImmunogenicity of ALVAC HIV (vcp1521) and AIDSVAX B/E Prime Boost Vaccination in RV144, Thai Phase III HIV Vaccine Trial
Immunogenicity of ALVAC HIV (vcp1521) and AIDSVAX B/E Prime Boost Vaccination in RV144, Thai Phase III HIV Vaccine Trial M. de Souza, R. Trichavaroj, A. Schuetz, W. Chuenarom, Y. Phuang ngern, S. Jongrakthaitae,
More informationAn Evaluation of Prescreen Recruitment Data: Enrolling Racial/Ethnic Minorities in Phase I HIV Vaccine Clinical Trials
An Evaluation of Prescreen Recruitment Data: Enrolling Racial/Ethnic Minorities in Phase I HIV Vaccine Clinical Trials Yesenia Merino, CCRC; Diane R. Johnson, MPH; Nina Berkowitz; Olga Vasilenko, MS, CCRP;
More informationNovel Vaccine Products for Planned Phase I Immunogenicity Studies in Infants
Office of AIDS Research Novel Vaccine Products for Planned Phase I Immunogenicity Studies in Infants L. Jean Patterson, PhD Office of AIDS Research, NIH February 7, 2017 Office of AIDS Research OAR Responsibilities
More informationGOVX-B11: A Clade B HIV Vaccine for the Developed World
GeoVax Labs, Inc. 19 Lake Park Drive Suite 3 Atlanta, GA 3 (678) 384-72 GOVX-B11: A Clade B HIV Vaccine for the Developed World Executive summary: GOVX-B11 is a Clade B HIV vaccine targeted for use in
More informationInnate and Cellular Immunology Control of Infection by Cell-mediated Immunity
Innate & adaptive Immunity Innate and Cellular Immunology Control of Infection by Cell-mediated Immunity Helen Horton PhD Seattle Biomedical Research Institute Depts of Global Health & Medicine, UW Cellular
More informationQuestions and answers: HVTN 110 vaccine study
1. What is a vaccine study? A vaccine teaches the body to prevent a particular infection or fight a disease. In order to develop a vaccine, researchers need to test it in people. A vaccine study tests
More informationProfessor Jonathan Weber
THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Professor Jonathan Weber Imperial College, London 1-4 April 2014, Arena and Convention Centre Liverpool THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Professor
More informationSupplementary Figure 1. ALVAC-protein vaccines and macaque immunization. (A) Maximum likelihood
Supplementary Figure 1. ALVAC-protein vaccines and macaque immunization. (A) Maximum likelihood tree illustrating CRF01_AE gp120 protein sequence relationships between 107 Envs sampled in the RV144 trial
More informationNovel Heterologous Prime-Boost Vaccine Strategies for HIV. Dan Barouch April 18, 2012
Novel Heterologous Prime-Boost Vaccine Strategies for HIV Dan Barouch April 18, 2012 Desired Features of a Next Generation HIV-1 Vaccine Candidate The RV1 study suggests that an HIV-1 vaccine is possible
More informationOverview of the Joint HVTN/HPTN Research Portfolio. Theresa Gamble, PhD HPTN LOC May 15, 2018
Overview of the Joint HVTN/HPTN Research Portfolio Theresa Gamble, PhD HPTN LOC May 15, 2018 1 Joint HVTN/HPTN mab Portfolio HVTN 130/HPTN 089 HVTN 703/HPTN 081 HVTN 704/HPTN 084 AMP (VRC01) HVTN 127/HPTN
More informationIdentification and Characterization of CD4 T cells actively transcribing HIV RNA in Peripheral Blood
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Identification and Characterization of CD4 T cells actively transcribing
More informationHIV Vaccine Clinical Trials at CIDRZ
HIV Vaccine Clinical Trials at CIDRZ Developing a Safe and Effective Vaccine for Prevention of HIV Infections Globally Christine Namakobo Senior Research Nurse Matero Clinical Research Site State of Global
More informationSocial and Behavioral Research in HVTN
Social and Behavioral Research in HVTN Michele P. Andrasik The HVTN is supported through a cooperative agreement with the National Institute of Allergy and Infectious Diseases HVTN MISSION To fully characterize
More informationUniversal Influenza Vaccine Development
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Universal Influenza Vaccine Development 2016 Global Vaccine and Immunization
More informationA Path to an HIV Vaccine: GSID Consortium Activities. Faruk Sinangil, PhD 4th Annual CAVD Meeting Miami, FL December 1-4, 2009
A Path to an HIV Vaccine: GSID Consortium Activities Faruk Sinangil, PhD 4th Annual CAVD Meeting Miami, FL December 1-4, 2009 Project Goals Acquire and disseminate information that will contribute to the
More informationESCMID Online Lecture Library. by author
Update and Prospects for CMV Vaccine Robert Pass University of Alabama at Birmingham ESCMID Postgraduate Course Centro Universitario Residenziale di Bertinoro 29 Sept 29 3 Oct 2013 Disclosures: Partial
More informationCurrent State of HIV Vaccine Development
Current State of HIV Vaccine Development Sandhya Vasan, MD US Military HIV Research Program Henry M. Jackson Foundation Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand AVAC HVAD
More informationBoosts Following Priming with gp120 DNA
Neutralizing Antibody Responses Induced with V3-scaffold Protein Boosts Following Priming with gp120 DNA Susan Zolla-Pazner NYU School of Medicine Problems with Whole Env Immunogens Poor induction of Abs
More informationHow Vaccines Work. Jerry Sadoff MD Crucell Vaccine Institute
How Vaccines Work Jerry Sadoff MD Crucell Vaccine Institute Questions you will be able to answer at the end of this session How do Vaccines Work? How do we develop vaccines? How do we manufacture vaccines?
More informationQuestions and answers: HVTN 084 vaccine trial
1. What is the HVTN 084 trial? Questions and answers: HVTN 084 vaccine trial Version 2 Last updated December 2, 2010 HVTN 084 is the name of a clinical trial to test the safety of 2 experimental HIV vaccines.
More informationHIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial
The Journal of Clinical Investigation Clinical Medicine HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial Pierre-Alexandre Bart, 1,2,11 Yunda Huang, 3,11 Shelly T. Karuna,
More informationVirus Panels for Assessing Vaccine-Elicited Neutralizing Antibodies
Virus Panels for Assessing Vaccine-Elicited Neutralizing Antibodies Michael Seaman, Ph.D. Center for Virology and Vaccine Research Beth Israel Deaconess Medical Center Harvard Medical School J. Virol.
More informationApplication of systems biology to identify predictors of HIV vaccine immunogenicity
Application of systems biology to identify predictors of HIV vaccine immunogenicity Daniel Zak 1, Erica Andersen-Nissen 2, Haesun Park 3, Scott Hansen 3, Karl Mullen 3, Kristi Hamilton 1, Kathleen Kennedy
More informationReview on vectored influenza vaccines. Sarah Gilbert Jenner Institute Oxford
Review on vectored influenza vaccines Sarah Gilbert Jenner Institute Oxford Viral Vectored Influenza Vaccines Can be used to induce antibodies against HA Will also boost CD4 + T cell responses against
More informationFostering Clinical Development for HIV-1 Vaccine
W Fostering Clinical Development for HIV-1 Vaccine Ravimiarenduse alane seminar 9. oktoobril Tallinnas Mart Ustav, PhD CSO, SVP 1 FIT Biotech Founded in 1995 Operations in Tampere, Finland and Tartu, Estonia
More informationHIV Prevention Strategies HIV Pre-exposure prophylaxis
HIV Prevention Strategies HIV Pre-exposure prophylaxis Michael Martin, MD, MPH Director HIV Research Program Thailand MOPH U.S. CDC Collaboration The findings and conclusions in this presentation are those
More informationAre we targeting the right HIV determinants?
QuickTime et un décompresseur TIFF (non compressé) sont requis pour visionner cette image. AIDS Vaccine 2009 October 22 nd 2009 - Paris Are we targeting the right HIV determinants? Françoise BARRÉ-SINOUSSI
More informationVaccine Trial Centre. Established in1984 Funded by WHO on Control of Diarrhea Diseases Full operation in1986
Vaccine Trial Centre Established in1984 Funded by WHO on Control of Diarrhea Diseases Full operation in1986 Past 29 Years of Research Experiences Cholera Vaccine Killed whole cell and B sub-unit oral vaccine
More informationFrom Antibody to Vaccine a Tale of Structural Biology and Epitope Scaffolds
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services From Antibody to Vaccine a Tale
More informationBiomedical Engineering for Global Health. Lecture 10 HIV/AIDS vaccine development
Biomedical Engineering for Global Health Lecture 10 HIV/AIDS vaccine development Review of lecture 9 How do vaccines work? Types ofvaccines: Review of lecture 9 Are vaccines effective? -Edward Jenner s
More informationH5N1 and H7 LAIV-IAV Prime-Boost Studies
NIAID H5N1 and H7 LAIV-IAV Prime-Boost Studies Kanta Subbarao, MD, MPH NIAID, NIH The LID Pandemic Influenza Vaccine Program Program: CRADA with MedImmune Clinical Trials: Center for Immunization Research,
More informationProgress on new vaccine strategies against chronic viral infections
Progress on new vaccine strategies against chronic viral infections Jay A. Berzofsky,, Masaki Terabe, Igor M. Belyakov J Clin Invest. 2004;114(4):450-462. https://doi.org/10.1172/jci22674. Review Among
More information24 26 January 2013, Hong Kong SAR, CHINA. TITLE from VIEW and SLIDE MASTER February 27, 2013
The first WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses 24 26 January 2013, Hong Kong SAR, CHINA 1 TITLE
More informationPreventive and therapeutic HIV vaccines. Markus Bickel Infektiologikum Frankfurt
Preventive and therapeutic HIV vaccines Markus Bickel Infektiologikum Frankfurt No conflicts to declare Disclosures Background FAQ: by patients and colleagues Publication about promising results, especially
More informationGene Vaccine Dr. Sina Soleimani
Gene Vaccine Dr. Sina Soleimani Human Viral Vaccines Quality Control Laboratory (HVVQC) Titles 1. A short Introduction of Vaccine History 2. First Lineage of Vaccines 3. Second Lineage of Vaccines 3. New
More informationAn AIDS vaccine: Why is it so difficult?
An AIDS vaccine: Why is it so difficult? Jaap Goudsmit, MD, PhD Professor of Poverty-related Communicable Diseases, AMC Chairman of the Board CPCD CSO, Crucell Holland BV An AIDS vaccine: Why is it so
More informationEMERGING ISSUES IN THE HUMORAL IMMUNE RESPONSE TO HIV. (Summary of the recommendations from an Enterprise Working Group)
AIDS Vaccine 07, Seattle, August 20-23, 2007 EMERGING ISSUES IN THE HUMORAL IMMUNE RESPONSE TO HIV (Summary of the recommendations from an Enterprise Working Group) The Working Group Reston, Virginia,
More informationNew Preventive Technology: Providing New Options to Stop the Spread of HIV/AIDS. Dublin, Ireland. June 24, AIDS Vaccines.
New Preventive Technology: Providing New Options to Stop the Spread of HIV/AIDS Dublin, Ireland June 24, 2004 AIDS Vaccines - An R&D Briefing This paper has been prepared by the International AIDS Vaccine
More informationDidactic Series. Immunizations in HIV Infected Individuals. Daniel Lee, MD UC San Diego, Owen Clinic 5/11/2017
Didactic Series Immunizations in HIV Infected Individuals Daniel Lee, MD UC San Diego, Owen Clinic 5/11/2017 Slides author: Ankita Kadakia, MD, AAHIVS 1 Learning Objectives To learn how vaccines induce
More informationCanadian Immunization Conference 2018 Dec 4
Enveloped Virus-Like Particle (evlp) Cytomegalovirus (CMV) Vaccine is immunogenic and safe: preliminary results of a First-in-Humans Canadian Immunization Network (CIRN) Clinical Trials Network (CTN) -
More informationThird Env Manufacturing Workshop July 20 21, July 20, 2017 Mary Marovich, M.D. Director, Vaccine Research Program
Third Env Manufacturing Workshop July 20 21, 2017 July 20, 2017 Mary Marovich, M.D. Director, Vaccine Research Program Presentation Outline Importance and Impact of an HIV Vaccine DAIDS/VRP Programmatic
More informationSafety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054)
Safety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054) Laurence Peiperl 1, Cecilia Morgan 2, Zoe Moodie 2,
More informationHIV Antibody Characterization for Reservoir and Eradication Studies. Michael Busch, Sheila Keating, Chris Pilcher, Steve Deeks
HIV Antibody Characterization for Reservoir and Eradication Studies Michael Busch, Sheila Keating, Chris Pilcher, Steve Deeks Blood Systems Research Institute University of California San Francisco, CA
More informationAlternate Antibody-Based Therapeutic Strategies To Purge the HIV Cell Reservoir
Alternate Antibody-Based Therapeutic Strategies To Purge the HIV Cell Reservoir Giuseppe Pantaleo, M.D. Professor of Medicine Head, Division of Immunology and Allergy Executive Director, Swiss Vaccine
More informationEvaluation of lead HIV-1 vaccine regimen in APPROACH:
Evaluation of lead HIV-1 vaccine regimen in : Phase 1/2a study testing heterologous prime boost regimens using mosaic Ad26 and MVA vectors combined with Env protein Hanneke Schuitemaker Martin Freeman,
More informationAntivirals and Vaccines: What s old and new in HSV-2 treatment
Antivirals and Vaccines: What s old and new in HSV-2 treatment Christine Johnston, MD, MPH Last Updated: January 19, 2018 uwptc@uw.edu uwptc.org 206-685-9850 Importance of HSV: Why pursue a vaccine? Prevention
More informationHow HIV Causes Disease Prof. Bruce D. Walker
How HIV Causes Disease Howard Hughes Medical Institute Massachusetts General Hospital Harvard Medical School 1 The global AIDS crisis 60 million infections 20 million deaths 2 3 The screen versions of
More informationComments made today contain forward looking statements as described under the Private Securities Litigation Reform Act of Our forward looking
EBOLA HIV January 2015 Comments made today contain forward looking statements as described under the Private Securities Litigation Reform Act of 1995. Our forward looking statements represent our current
More informationHIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case cohort analysis
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case cohort analysis M Juliana McElrath, Stephen C De Rosa, Zoe Moodie, Sheri Dubey, Lisa Kierstead, Holly Janes, Olivier D Defawe, Donald
More informationDevelopment of live attenuated pediatric RSV vaccines
Development of live attenuated pediatric RSV vaccines Laboratory of Infectious Diseases, NIAID, NIH (Ursula Buchholz, Peter Collins) Center for Immunization Research, JHU (Ruth Karron) Infant with RSV
More informationEDCTP Third Forum PARTNERSHIP AND AFRICAN LEADERSHIP IN VACCINE RESEARCH AND HIV/AIDS DRUG. MBOUP Souleymane
EDCTP Third Forum PARTNERSHIP AND AFRICAN LEADERSHIP IN VACCINE RESEARCH AND HIV/AIDS DRUG MBOUP Souleymane HIV VACCINE IN AFRICA In 2005, 13 new trials of preventive AIDS vaccine candidates began in 9
More informationReceived 15 November 2000; revised 6 February 2001; electronically published
1343 Safety and Immunogenicity of a Canarypox-Vectored Human Immunodeficiency Virus Type 1 Vaccine with or without gp120: A Phase 2 Study in Higher- and Lower-Risk Volunteers Robert B. Belshe, 1 Cladd
More informationProfessor Andrew McMichael
BHIVA AUTUMN CONFERENCE 2011 Including CHIVA Parallel Sessions Professor Andrew McMichael University of Oxford 17 18 November 2011, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE
More informationCombination prevention: Public health and human rights imperatives
Combination prevention: Public health and human rights imperatives Gottfried Hirnschall, MD MPH HIV/AIDS Department WHO, Geneva London, June 11, 2012 Outline The epidemic and response What is combination
More informationABSTRACT. n engl j med 369;22 nejm.org november 28,
The new england journal of medicine established in 1812 november 28, 2013 vol. 369 no. 22 Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Scott M. Hammer, M.D., Magdalena E. Sobieszczyk, M.D., M.P.H., Holly
More informationDNA and Protein Vaccination Confers Protection Upon Mucosal Challenge with Heterologous SIVsmE660 (OA 10.04)
DNA and Protein Vaccination Confers Protection Upon Mucosal Challenge with Heterologous SIVsmE660 (OA 10.04) Rashmi Jalah Human Retrovirus Pathogenesis Section, Vaccine Branch, CCR, National Cancer Institute
More informationHIV Anti-HIV Neutralizing Antibodies
,**/ The Japanese Society for AIDS Research The Journal of AIDS Research : HIV HIV Anti-HIV Neutralizing Antibodies * Junji SHIBATA and Shuzo MATSUSHITA * Division of Clinical Retrovirology and Infectious
More informationOn an individual level. Time since infection. NEJM, April HIV-1 evolution in response to immune selection pressures
HIV-1 evolution in response to immune selection pressures BISC 441 guest lecture Zabrina Brumme, Ph.D. Assistant Professor, Faculty of Health Sciences Simon Fraser University http://www3.niaid.nih.gov/topics/hivaids/understanding/biology/structure.htm
More informationPre-clinical Development of a Dengue Vaccine. Jeremy Brett Sanofi Pasteur, Singapore
Pre-clinical Development of a Dengue Vaccine Jeremy Brett Sanofi Pasteur, Singapore Dengue Vaccine B Guy 1 Talk flow Introduction: What are the challenges of dengue vaccine development? The Virus The host
More informationSAMRC S RESPONSE TO HIV & TB: WALKING THE TALK: MOVING TO CONTROL
SAMRC S RESPONSE TO HIV & TB: WALKING THE TALK: MOVING TO CONTROL Glenda Gray President & CEO SAMRC 1 SA AIDS 2017 Durban 15 June 2017 Partner logo LEADERSHIP IN A TIME OF UNCERTAINTY 2 BASELINE BUDGET
More informationOn the Horizon for Consideration: Biomedical Advances in HIV Prevention
On the Horizon for Consideration: Biomedical Advances in HIV Prevention Francisco Ruiz, MS Senior Manager, National Alliance of State and Territorial AIDS Directors New Jersey Governor's Advisory Council
More informationIt has been 25 years since HIV-1 was identified as the causative
Vol 4j2 October 8jdoi:.38/nature732 Challenges in the development of an HIV-1 vaccine Dan H. Barouch 1 The development of a safe and effective human immunodeficiency virus (HIV)-1 vaccine is a critically
More informationWhere We Have Been and Where We are Going. Ian McGowan MD PhD FRCP
Where We Have Been and Where We are Going Ian McGowan MD PhD FRCP Directions Where we were Where we are headed Where we are 2005 The size of your dreams must always exceed your current capacity to achieve
More informationUpdate on Biomedical Prevention. Thomas C. Quinn, MD, MSc
Update on Biomedical Prevention Thomas C. Quinn, MD, MSc Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health
More informationCase study of formulating two Subtype C gp120 proteins
Case study of formulating two Subtype C gp120 proteins Antu Dey, DPhil. Senior Director, IAVI (formerly at GSK Vaccines) Associate Project Leader HIV Research Head Formulation Sciences & Process Development
More informationMulti-Virus-Specific T cell Therapy for Patients after HSC and CB Transplant
Multi-Virus-Specific T cell Therapy for Patients after HSC and CB Transplant Hanley PJ, Krance BR, Brenner MK, Leen AM, Rooney CM, Heslop HE, Shpall EJ, Bollard CM Hematopoietic Stem Cell Transplantation
More informationNK mediated Antibody Dependent Cellular Cytotoxicity in HIV infections
NK mediated Antibody Dependent Cellular Cytotoxicity in HIV infections Amy Chung Dr. Ivan Stratov Prof. Stephen Kent ADCC process consists of Target cell QuickTime and a TIFF (Uncompressed) FcγR decompressor
More informationHIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP
HIV: Pregnancy in Serodiscordant Couple Dr Chow TS ID Clinic HPP Sexual Reproductive Health and Rights The recognition of the sexual and reproductive health and rights (SRHR) of all individuals and couples
More informationDevelopment of a Recombinant Subunit Dengue Vaccine. Flavivirus Vaccination Fondation Mérieux December 8, 2010 Beth-Ann Coller
Development of a Recombinant Subunit Dengue Vaccine Flavivirus Vaccination Fondation Mérieux December 8, 2010 Beth-Ann Coller Recombinant Subunit Dengue Vaccine Recombinant Envelope Protein Vaccine Hawaii
More information